XYRATEX LTDNOTES TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(U.S. dollars and amounts in thousands, except per share data, unless otherwise stated)10. Ordinary Shares and Stock Option plans (Continued)The <strong>Xyratex</strong> Group Limited shares in issue after the private equity investment and prior to theIPO were subject to varying rights upon a sale, listing, or liquidation (a ‘‘conversion’’ event) as follows.On a conversion event a pro rata portion of class A preferred ordinary shares, class B preferredordinary shares and class C ordinary shares were to be effectively cancelled to achieve the followingreturns. Holders of class B preferred ordinary shares were to receive value of £4.51 per share beforeany other shareholders. The class A preferred ordinary shareholders were to receive the next £4.51 pershare. Any value remaining would next be distributed equally to holders of class A and B preferredordinary shares equal to a return of 10% per annum, accruing annually on £4.51 per share. Finally, anyfurther value would be transferred pro rata to all holders of <strong>Xyratex</strong> Group Limited shares. To theextent that holders of class B preferred ordinary shares received a return of more than 100% of theirinitial investment within twelve months of a conversion event, more than 150% between twelve and24 months from a conversion event, or 200% after 24 months from a conversion event, then 25% ofthe excess of the applicable return was to be transferred to class C shareholders.Share RepurchaseAs part of the private equity transaction described above the Company acquired 1,856 class Bshares and 805 class A shares at a cost of $18,939 in the year ended November 30, 2003.Employee Stock Purchase planThe Company introduced an employee stock purchase plan (the ‘‘ESPP’’) in May 2002, underwhich any eligible employee of the Company receives the rights to purchase the Company’s shares. Apurchase right entitles a participant to purchase at the end of each offering period, subsequent to theIPO each fiscal quarter, the number of common shares determined by dividing the participant’saccumulated payroll deductions in his or her plan account by the purchase price for that offeringperiod. Generally, the per share purchase price is 85% of the lower of the fair market value of onecommon share on the first trading day of the offering period or the fair market value of such a shareon the last trading day of the offering period. The payroll deductions may not exceed two hundreddollars per pay period per employee, and an employee may not purchase more than $25 of fair value ofshares in any annual period. The ESPP terminates in December 2021.Rights granted under the ESPP prior to the scheme of arrangement and IPO in June 2004 wereaccounted for as variable awards over junior stock. Compensation expense related to these stockpurchase rights was recognized when the transferability restrictions on the underlying <strong>Xyratex</strong> GroupLimited class A preferred ordinary shares to be issued upon exercise of these rights lapsed. Nocompensation expense arises in connection with this plan subsequent to the IPO. There were 29, 36and 27 shares awarded under this plan in the years ended November 30, 2005, 2004 and 2003,respectively.Restricted SharesRestricted share awards are awards of our common shares that will vest in accordance with termsand conditions established by the board of directors. The board of directors may impose whateverconditions to vesting it determines to be appropriate. For example, the board of directors may setF-28
XYRATEX LTDNOTES TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(U.S. dollars and amounts in thousands, except per share data, unless otherwise stated)10. Ordinary Shares and Stock Option plans (Continued)restrictions based on the achievement of specific performance goals. Unvested shares will be subject toour right of repurchase or forfeiture.As described in note 4 the Company granted rights to restricted shares to six employees recruitedto develop intellectual property acquired from Cap Epsilon in April 2005. The Company granted rightsto 190 shares at no cost and which will vest based on the achievement of certain revenue targets overthe three years ended August 31, 2008. In addition the Company granted rights to 5 restricted shares toemployees of the acquired Oliver Design business. No expense has been recorded in connection withthese awards because the Company does not consider it probable that the related performance criteriawill be met.At November 30, 2005, 195 awards of restricted shares were outstanding.Share Option PlansThe Company has five plans under which employees have been granted options to purchase<strong>Xyratex</strong> Group Limited ordinary shares or <strong>Xyratex</strong> Limited common shares. As part of the scheme ofarrangement all options to purchase <strong>Xyratex</strong> Group Limited shares were exchanged for options topurchase <strong>Xyratex</strong> Limited shares in same ratios as the exchange of shares. As described above, optionsto purchase <strong>Xyratex</strong> Group Limited shares have been accounted for as variable awards over juniorstock. Compensation expense relating to these awards, to the extent vested, has been recognized in theCompany’s Consolidated Statements of Operations on the removal of transferability restrictions overthe underlying shares on the effectiveness of the scheme of arrangement in June 2004. In addition, foroptions which were exercised and then sold to HgCapital in September 2003, compensation expense of$3,656 was recognized in the year ended November 30, 2003 as a result of the related removal oftransferability restrictions over the shares sold. Of this amount $758 is included in discontinuedoperations.The Company and Credit Suisse First Boston, the managing underwriter for the IPO, have agreedto impose a limit on the number of common shares over which options may be granted, to the effectthat the total number of common shares over which options may be granted under all of theCompany’s share option, share purchase, restricted stock and stock bonus award plans shall not, in anyconsecutive ten year period, commencing after the IPO, exceed 5,632,648. Lapsed and surrenderedoptions are disregarded for these purposes. At January 31, 2006, options over 1,503,000 common shareshad been granted since the IPO. Where the number of options which can be granted under a specificplan is subject to a limit then these limits are stated below.During the year ended November 30, 2005, 394 common shares were issued to employees to satisfyshare options and an employee share purchase plan.On January 10, 2005 the Company granted 953 options over common shares to its employees at anexercise price of $14.31, being the market price on that date.On May 23, 2005 the Company agreed to grant 90 options over common shares to new employeesat an exercise price of $15.77, being the market price on that date. In addition 5 restricted shares wereawarded to one employee at no cost.F-29
- Page 3:
XYRATEX LTDANNUAL REPORT FOR THE YE
- Page 6 and 7:
INTRODUCTIONWe are incorporated und
- Page 8 and 9:
Year Ended November 30,2005 2004 20
- Page 10 and 11:
The computations for the weighted a
- Page 12 and 13:
The markets in which we operate are
- Page 14 and 15:
technological capabilities. This co
- Page 16 and 17:
may cease production of components,
- Page 18 and 19:
• potentially adverse tax consequ
- Page 20 and 21:
We could incur substantial costs, i
- Page 22 and 23:
influence by voting at a meeting of
- Page 24 and 25:
Xyratex Ltd to the former sharehold
- Page 26 and 27:
In addition to the rapid growth of
- Page 28 and 29:
RAID controller technology is proje
- Page 30 and 31:
Our Competitive StrengthsDisk drive
- Page 32 and 33:
the storage subsystem and disk driv
- Page 34 and 35:
Our storage subsystems are internal
- Page 36 and 37:
systems are capable of testing a fu
- Page 38 and 39:
Research and DevelopmentWe have ove
- Page 40 and 41:
• sets forth procedures for the p
- Page 42 and 43:
Item 4C: Organization StructureXyra
- Page 44 and 45:
ecame the parent company of our bus
- Page 46 and 47:
Foreign Exchange Rate FluctuationsT
- Page 48 and 49:
we recorded in the year ended Novem
- Page 50 and 51:
Fiscal Year Ended November 30, 2005
- Page 52 and 53:
Research and Development—otherThe
- Page 54 and 55:
Fiscal Year Ended November 30, 2004
- Page 56 and 57:
Selling, General and Administrative
- Page 58 and 59:
Quarterly Results of OperationsThe
- Page 60 and 61:
sales growth. The increase in defer
- Page 62 and 63:
choose to make or alliances we have
- Page 64 and 65:
compete. Identifiable intangible as
- Page 66 and 67:
ITEM 6: DIRECTORS, SENIOR MANAGEMEN
- Page 68 and 69: Ernest Sampias has served as a dire
- Page 70 and 71: Audit CommitteeOur Audit Committee
- Page 72 and 73: Employee Benefit/Share Option Plans
- Page 74 and 75: The maximum amount that any partici
- Page 76 and 77: Restricted StockRestricted stock aw
- Page 78 and 79: the options, warrants or rights, bu
- Page 80 and 81: Quarterly high and low market price
- Page 82 and 83: whose functional currency is not th
- Page 84 and 85: on the Nasdaq National Market and,
- Page 86 and 87: Interest RatesWe had cash and cash
- Page 88 and 89: aggregate in any fiscal year and th
- Page 90 and 91: (This page has been left blank inte
- Page 92 and 93: XYRATEX LTDAUDITED CONSOLIDATED BAL
- Page 94 and 95: F-4XYRATEX LTDAUDITED CONSOLIDATED
- Page 96 and 97: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 98 and 99: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 100 and 101: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 102 and 103: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 104 and 105: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 106 and 107: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 108 and 109: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 110 and 111: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 112 and 113: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 114 and 115: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 116 and 117: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 120 and 121: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 122 and 123: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 124 and 125: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 126 and 127: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 128 and 129: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 130: (This page has been left blank inte